Healthcare-associated pneumonia (HCAP) represents a type of pneumonia that occurs owing to prior contact with a healthcare environment. It is associated with several risk factors, including home infusion therapy, dialysis, hospitalization in the past, residing in a nursing center, immunocompromised state, etc. HCAP is characterized by unease, reduced appetite, cough with greenish or mucus-like phlegm, unpleasantness, abdominal discomfort, and difficulty breathing. Other symptoms include sharp chest pain that worsens with inhalation and exhalation or coughing, diminished blood pressure, and an increased heart rate. Diagnosing this condition begins with a chest x-ray or CT scan to examine the lungs and arterial blood gases to calculate the respiratory rate. It is accompanied by a sputum culture to detect the microorganisms provoking pneumonia and a pulse oximetry test to observe blood oxygen levels. The diagnosis also involves bronchoscopy, which is crucial to avoid the possibility of an incorrect prognosis.
Ask an Analyst for Report Customization with TOC & List of figures: [FURL=https://bit.ly/3o9VfIU]https://bit.ly/3o9VfIU[/FURL]
Market Trend:
The escalating prevalence of chronic ailments, such as cardiac arrest, brain stroke, kidney failure, etc., requiring surgical intervention and prolonged hospital stays, is primarily driving the healthcare-associated pneumonia market. Besides this, the rising number of patients admitted to medical facilities who have antibacterial resistance, on account of the excessive usage of antibiotics, is further augmenting the market growth. Moreover, the growing popularity of various PCR-based platforms for diagnosing HCAP, which offers high detection efficiency, thereby reducing cost and time, is also catalyzing the global market.
Apart from this, the extensive utilization of combination therapy to treat this condition, since it reduces the chances of resistance developed by the bacteria and provides a broad spectrum of coverage, is acting as another significant growth-inducing factor. Furthermore, the elevating requirement for point-of-care testing products, owing to their convenience, quicker diagnosis, and improved patient outcomes, is expected to bolster the healthcare-associated pneumonia market in the coming years.
Request a Free Sample Report: [URL=https://www.imarcgroup.com/healthcare-associated-pneumonia-market/requestsample]https://www.imarcgroup.com/healthcare-associated-pneumonia-market/requestsample[/URL]
Key Questions Answered in this Report:
How has the healthcare-associated pneumonia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
What was the country-wise size of the healthcare-associated pneumonia market across the seven major markets in 2022 and what will it look like in 2033?
What is the growth rate of the healthcare-associated pneumonia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
About Us: –
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
Contact US
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 |